FA: Musculoskeletal, Skin, CT Drugs Flashcards
Acetaminophen
MOA: reversibly inhibits cyclooxygenase, mostly in the CNS; inactivated peripherally
Clinical Use: antipyretic, analgesic, but NOT anti-inflammatory; used instead of aspirin to avoid Reye’s syndrome in those under 20 with viral infections
Toxicity: overdose produces hepatic necrosis; acetaminophen metabolite (NAPQ1) depletes glutathione and forms toxic tissue by-products in the liver. N-acetylcysteine is the antidote - it regenerates glutathione
Aspirin
MOA: irreversibly inhibits cyclooxygenase (both COX-1 and COX-2) via acetylation, which decreases the synthesis of TXA2 and prostaglandins; increases bleeding time; no effect on PT, PTT; a type of NSAID
Clinical Use: low dose (
Celecoxib
MOA: reversibly inhibits specifically the cyclooxgenase (COX) isoform 2, which is found in inflammatory cells and vascular endothelium and mediates inflammation and pain; spares COX-1, which helps maintain gastric mucosa. Thus, does not have the corrosive effects of other NSAIDs on the GI lining; spares platelet function as TXA2 production is dependent on COX-1
Clinical Use: rheumatoid arthritis, osteoarthritis
Toxicity: increased risk of thrombosis; sulfa allergy
NSAIDs: Ibuprofen, naproxen, indomethacin, ketorolac, diclofenac
MOA: reversibly inhibit cyclooxygenase (both COX-1 and COX-2); block prostaglandin synthesis
Clinical Use: antipyretic, analgesic, anti-inflammatory; indomethacin is used to close a PDA
Toxicity: interstitial nephritis, gastric ulcer (prostaglandins protect the gastric mucosa); renal ischemia (prostaglandins vasodilate the afferent arteriole)
Bisphosphonates: Alendronate (-dronate)
MOA: pyrophosphate analogs; bind hydroxyapatite in bone, inhibiting osteoclast activity
Clinical Use: osteoporosis, hypercalcemia, Paget disease of bone
Toxicity: corrosive esophagitis (patients are advised to take with water and remain upright for 30 min); osteonecrosis of the jaw
Teriparatide
MOA: recombinant PTH analog given subcutaneously daily; increases osteoblast activity
Clinical Use: osteoporosis; causes increased bone growth compared to anti-resorptive therapies (bisphosphonates)
Toxicity: transient hypercalcemia; may increase risk of osteosarcoma (seen in rodent studies)
Drugs for Gout
Allopurinol, febuxostat, pegloticase, probenecid
Allopurinol
Inhibits xanthine oxidase after being converted to alloxanthine; decreases conversion of xanthine to uric acid; also used in lymphoma and leukemia to prevent tumor lysis-associated urate nephropathy; increases concentrations of azathioprine and 6-MP (both normally metabolized by xanthine oxidase)
Febuxostat
Inhibits xanthine oxidase
Pegloticase:
Recombinant uricase that catalyzes metabolism of uric acid to allantoin (a more water-soluble product)
Probenecid
Inhibits reabsorption of uric acid in proximal convoluted tubule (also inhibits secretion of penicillin); can precipitate uric acid calculi
Acute Gout Drugs
NSAIDs, glucocorticoids (oral or intra-articular), colchicine
Do NOT give salicylates; all but the highest doses depress uric acid clearance; even high doses (5-6 g/day) have only minor uricosuric activity
Colchicine
Binds and stabilizes tubulin to inhibit microtubule polmerization, impairing neutrophil chemotaxis and degranulation
Acute and prophylactic value
GI side effects
TNF-a Inhibitors
Etanercept, Infliximab, Adalimumab
Etanercept
Fusion protein (receptor for TNFa + IgG1Fc) produced by recombinant DNA (EtanerCEPT is a TNF decoy reCEPTor) Clinical use: rheumatoid arthritis, psoriasis, ankylosing spondylitis